Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the U
Perelman School of Medicine
Emily Conant of the Perelman School of Medicine is quoted about testing for breast cancer and the legislation in some s
Joan O’Brien of the Perelman School of Medicine discusses leading a study about the genetics of glaucoma in African Ame
Ezekiel Emanuel of the Perelman School of Medicine and the Wharton School co-authors an article sharing his thoughts on
Marcela Maus of the Perelman School of Medicine comments on a study about a personalized immune therapy that redirects
Ellen Freeman of the Perelman School of Medicine discusses menopause and hot flashes.
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Scienc